

Directions



Traveling south on Freeway 99 (from Northern California)

Once you arrive in the Fresno area, take Herndon exit. Turn left onto Herndon Avenue. Stay on Herndon to Millbrook Ave. (approximately 9 miles). Turn right onto Frontage Road.

Traveling north on Freeway 99 to Highway 41 (from Southern California)

Once you arrive in the Fresno area, take Herndon exit. Turn right onto Herndon Avenue to Millbrook Ave. (approximately 1 mile). Turn right onto Frontage Road.

Register

Saint Agnes Medical Center Staff, Nurses and Allied Health Professionals – **No charge**
VA Hospital Physicians, Nurses and Affiliated Healthcare Staff – **No charge**
Non-Saint Agnes Physicians – **No charge** • Nurses/Others – **No charge**

Preregistration is required. Please register online at www.samc.com. Registration must be received by March 12, 2012, to be guaranteed a participant syllabus. If you have questions or problems registering online, send an e-mail to medicaleducation@samc.com or call (559) 450-7566.

Registration at the door is dependent on space availability.

6.0 AMA PRA Category 1 Credits™ to be awarded

Non-Profit Org.
U.S. Postage
PAID
Fresno, CA
Permit No. 280



**Saint Agnes
Medical Center**
1303 E. Herndon Ave.
Fresno, CA 93720

ADDRESS SERVICE REQUESTED


4th Annual Central California Cardiometabolic Risk Symposium

Treatment of the High-Risk Patient with Low HDL-c



Saint Agnes
Medical Center

California
Cardiovascular
Institute



4th Annual

Central California Cardiometabolic Risk Symposium

Treatment of the High-Risk Patient with Low HDL-c

Saturday, March 17, 2012

7:30 a.m.-3:30 p.m.

Saint Agnes Medical Center

Shehadey Pavilion

1303 E. Herndon Ave., Fresno, Calif.

Attend the **most comprehensive cardiometabolic risk management event in the Central Valley!**

Presented by:

Saint Agnes Medical Center

Medical Education Program

California Cardiovascular Institute

John R. Nelson, MD, FACC, Program Director

Teaching Objectives

- **Describe** the protein structure of HDL and how it relates to its functionality.
- **Interpret** measurements of HDL functionality and how they may become important clinical tools.
- **Explain** how to use different modalities in getting patients with Diabetes Mellitus to their HDL-c goal.
- **Discuss** the role of fish oil and fibrates in the treatment of high-risk patients with low HDL-c, including specific subgroups, which have shown benefits.
- **Appraise** the role of Nicotinic Acid in the treatment of the high-risk patient with low HDL-c.
- **Assess** the role of cardiovascular imaging in enhancing the identification of high-risk patients and also to help determine treatment plans.
- **Demonstrate** the advantages of advanced lipid testing in high-risk patients with low HDL-c in enhancing treatment with combination therapy.

Target Audience

Primary care physicians, endocrinologists, obesity specialists, nurse practitioners, nurses, pharmacists, and other healthcare professionals who are interested in the treatment of patients with cardiometabolic risk factors and related cardiometabolic complications.

Program Moderator

John R. Nelson, MD, FACC

Director, California Cardiovascular Institute; President-Elect, Pacific Lipid Association; Assistant Clinical Professor, UCSF School of Medicine; Fresno Medical Residency Program – Volunteer; Symposium Program Director, Fresno, Calif.

7:30 a.m. • Registration / Breakfast / Exhibits

8:00 • Welcome / Introduction

John Nelson, MD

8:15

HDL and Its Galaxy of Proteins: What Do They Do?

Jay Heinecke, MD, Professor, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington School of Medicine, Seattle, Wash.

9:00

HDL Functionality: Where Are We Towards Clinical Application?

Michael Oda, PhD, Associate Staff Scientist, Children's Hospital Oakland Research Institute, Oakland, Calif.

9:45

Achieving HDL-c Goal in Patients with Diabetes Mellitus

Paul Rosenblit, MD, Endocrinologist, Huntington Beach, Calif, specializing in diabetes, metabolism, endocrinology and internal medicine

10:30 • Break / Exhibits

11:00

The Role of Fish Oil and Fibrates in the Treatment of the High-Risk Patient with Low HDL-c

Dr. J. Antonio G. Lopez, MD, Director of Preventive Cardiology and Cardiovascular Rehabilitation, Medical Director, Lipid Clinic Services, Saint Alphonsus Regional Medical Center, Boise, Idaho

11:45

The Role of Nicotinic Acid in the Treatment of the High-Risk Patient with Low HDL-c

John Nelson, MD

12:30 p.m. • Lunch / Exhibits

1:15

The Role of Cardiovascular Imaging (MRI, CIMT, CTA) in the High-Risk Patient with Low HDL-c

B. Bottenberg, DO, FACOI, FNLA, Northern Nevada Lipidology, Internal Medicine Associates, Carson City, Nevada

2:00

Density Gradient Lipoproteins: Lipids and proteins

Michael Cobble, MD, Director, Canyons Medical Center, Sandy, Utah; Diplomat of the American Board of Clinical Lipidology; Chief Medical Officer, Atherotech Diagnostics Lab

2:45

Impact of Lifestyle in Modification of HDL-c in High-Risk Patients

Thomas Bersot, MD, PhD, Associate Investigator, Gladstone Institute of Cardiovascular Disease, Clinical Professor of Medicine, University of California, San Francisco

3:00 • Q & A / Adjournment

Accreditation Statement

Saint Agnes Medical Center is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. Saint Agnes Medical Center takes responsibility for the content, quality and scientific integrity of this CME activity. Saint Agnes Medical Center designates this live symposium for a maximum of **6.0 AMA PRA Category 1 Credits**.™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit also may be applied to the CMA Certification in Continuing Medical Education. Each physician should only claim those hours of credit that he or she actually spent in the educational activity. Saint Agnes Medical Center is approved by the California Board of Registered Nursing as a provider of continuing education under Provider No. 00262. **6.0 CE contact hours** are approved for this course.

NLA Statement

The National Lipid Association is recognized to endorse the credit hours offered by this activity as "lipid-focused" continuing medical education that meets the credentialing and certification standards established by the American Board of Clinical Lipidology (www.lipidboard.org) and the Accreditation Council for Clinical Lipidology (www.lipidspecialist.org)

